share_log

Novartis will spend up to 1.7 billion USD to acquire the biotechnology company Regulus Therapeutics.

Breakings ·  Apr 30 20:17

On April 30, Novartis announced an agreement to acquire the USA biotechnology company Regulus Therapeutics. The trade includes an upfront payment of 0.8 billion USD, with up to an additional 0.9 billion USD potentially payable upon reaching future regulatory milestones. The transaction is expected to be completed in the second half of this year. Regulus is committed to developing microRNA therapies focused on treating autosomal dominant polycystic kidney disease (ADPKD).

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment